GTHX G1 Therapeutics Inc

4,795

$1.34

$0.10

(6.94%)

Today

Watchers	4,795
52-Wk Low	$1.17
52-Wk High	$13.85

Market Cap	$74.51M
Volume (M)	235,743.00
52-Wk High	$13.85
52-Wk Low	$1.17

Fundamentals

G1 Therapeutics, Inc. (NASDAQ:GTHX) Given Average Rating of "Moderate Buy" by AnalystsTicker Report • 4 days ago

G1 Therapeutics, Inc. (NASDAQ:GTHX Get Free Report) has been assigned a consensus recommendation of Moderate Buy from the six research firms that are presently covering the...

Share to Feed

Black Diamond Therapeutics Announces CEO TransitionGlobe Newswire • 14 days ago

Current Chairman of the Board and industry veteran Mark Velleca appointed CEO CAMBRIDGE, Mass. and NEW YORK, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a...

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Globe Newswire • about 1 month ago

RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options...

G1 Therapeutics, Inc. (NASDAQ:GTHX) Receives $11.80 Consensus Price Target from AnalystsZolmax • about 1 month ago

Shares of G1 Therapeutics, Inc. (NASDAQ:GTHX Get Free Report) have received a consensus rating of Moderate Buy from the six brokerages that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and five have given a buy ...

G1 Therapeutics, Inc. (NASDAQ:GTHX) Shares Sold by Landscape Capital Management L.L.C.Zolmax • about 1 month ago

Landscape Capital Management L.L.C. lessened its holdings in shares of G1 Therapeutics, Inc. (NASDAQ:GTHX Free Report) by 31.3% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 38,569 shares of the companys stock after...

Q3 2023 Earnings Estimate for G1 Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:GTHX)Ticker Report • about 2 months ago

G1 Therapeutics, Inc. (NASDAQ:GTHX Free Report) Research analysts at HC Wainwright boosted their Q3 2023 earnings estimates for shares of G1 Therapeutics in a research report issued on Thursday, August 3rd. HC Wainwright analyst E. White now anticipates that the company will earn ($0...

G1 Therapeutics, Inc. (NASDAQ:GTHX) to Post Q3 2023 Earnings of ($0.24) Per Share, Wedbush ForecastsTicker Report • about 2 months ago

G1 Therapeutics, Inc. (NASDAQ:GTHX Free Report) Research analysts at Wedbush lifted their Q3 2023 earnings per share (EPS) estimates for G1 Therapeutics in a report released on Wednesday, August 2nd. Wedbush analyst D. Nierengarten now expects that the company will post earnings of...

Analysts Are Bullish on Top Healthcare Stocks: Cerevel Therapeutics Holdings (CERE), G1 Therapeutics (GTHX)TipRanks Financial Blog • 2 months ago

Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cerevel Therapeutics Holdings (CERE Research Repor... Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cerevel Therapeutics Holdings (CERE Research Report...

G1 Therapeutics Provides Second Quarter 2023 Financial Results and Operational HighlightsGlobe Newswire • 2 months ago

- Recognized Total Revenue of $42.4 Million, Including $11.1 Million in Net COSELA (trilaciclib) Revenue - - Reiterated Expectation for Interim Overall Survival (OS) Analysis of Pivotal Phase 3 Trial in Metastatic Triple Negative Breast Cancer (TNBC) in the First Quarter of 2024 - - Presented New ...